MabVax Therapeutics sublicenses therapeutics for patented neuroblastoma vaccine
US clinical-stage oncology drug developer MabVax Therapeutics has granted to Denmark-based Y-mAbs Therapeutics…
Related Articles
- Cancer-killing virus therapy may be improved by low dose of targeted drug also categorized in Drug
- GRHL1 acts as tumor suppressor in neuroblastoma and is negatively regulated by MYCN and HDAC3. also categorized in Drug
- Anti-tumor activity of safranal against neuroblastoma cells. also categorized in Drug
- Efficacy and safety of micafungin for the prophylaxis of invasive fungal infection during neutropenia in children and adolescents undergoing allogeneic hematopoietic SCT. also categorized in Drug
- MabVax Therapeutics Receives Orphan Drug Designation for Therapeutic Vaccine to Treat Childhood Cancer Neuroblastoma also mentions Vaccine
- Modified blood-thinning drug could target neuroblastoma | Cancer Research UK also categorized in Drug
- BRIEF—Cellectar gets Rare Pediatric Disease designation for CLR 131 also written by The Pharma Letter
- Research group urges EMA to mandate pediatric cancer trials also written by The Pharma Letter
- Nanoparticles used to enhance chemotherapy also categorized in Drug
- Treatment of chronic graft versus host disease with bortezomib. also categorized in Drug